Physician profile
Oren Zaidel
NPI 1689602195
$7,986.25
in general payments reported to CMS, 2019-2025
32 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $556 · 2021: $1,151 · 2022: $1,614 · 2023: $1,199 · 2024: $1,186 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.83 |
| Education | $189.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,733.46 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,136.20 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $929.67 | 2020-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $450.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $418.57 | 2019-2024 | Dificid |
| Ardelyx, INC. | $258.80 | 2022-2025 | Ibsrela |
| Celgene Corporation | $250.92 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $248.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $207.50 | 2019-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $193.87 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $181.94 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.35 | 2019-2022 | |
| Pfizer INC. | $105.01 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $89.89 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $71.22 | 2023-2025 | Vowst, Zenpep |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $70.39 | 2023-2024 | Yuflyma, Zymfentra |
| Amgen INC. | $68.17 | 2021 | |
| Organon LLC | $62.31 | 2021-2024 | Renflexis |
| Redhill Biopharma INC. | $58.92 | 2020-2024 | Talicia |
| Fresenius Kabi USA, LLC | $56.71 | 2023 | Idacio |
| Romark Laboratories, Lc | $36.36 | 2019 | |
| Shionogi INC | $32.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.68 | 2025 | Dupixent |
| 3-D Matrix, INC. | $29.74 | 2024 | |
| Alfasigma USA, INC. | $24.75 | 2020-2021 | |
| Qol Medical, LLC | $22.86 | 2022 | |
| Nestle Healthcare Nutrition INC. | $22.67 | 2022 | |
| Csl Behring | $19.15 | 2019 | |
| Lucid Diagnostics INC. | $16.76 | 2022 | |
| Intra-Sana Laboratories | $16.21 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Alnylam Pharmaceuticals INC. | $15.90 | 2022 | |
| Braintree Laboratories, INC. | $15.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oren Zaidel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.